Shares of Synthetic Biologics Inc (NYSEAMERICAN:SYN) saw unusually-strong trading volume on Monday . Approximately 932,833 shares traded hands during trading, an increase of 196% from the previous session’s volume of 315,450 shares.The stock last traded at $0.91 and had previously closed at $0.82.
A number of research analysts recently commented on SYN shares. HC Wainwright restated a “buy” rating and set a $35.00 price objective on shares of Synthetic Biologics in a research note on Thursday, August 9th. Zacks Investment Research upgraded Synthetic Biologics from a “hold” rating to a “buy” rating and set a $0.25 price target for the company in a research report on Tuesday, August 14th.
Synthetic Biologics (NYSEAMERICAN:SYN) last announced its quarterly earnings results on Wednesday, August 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.40) by $0.35.
About Synthetic Biologics (NYSEAMERICAN:SYN)
Synthetic Biologics, Inc, a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C.
Featured Story: Bear Market – How and Why They Occur
Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.